Advertisement

FDA Completes Safety Review of Olmesartan — Physician’s First Watch

Medical News |
June 26, 2014

FDA Completes Safety Review of Olmesartan

By Larry Husten

Edited by Susan Sadoughi, MD, and Lorenzo Di Francesco, MD, FACP, FHM

The FDA announced on Tuesday that it has completed its safety review of the antihypertensive drug olmesartan (sold as Benicar and others). The investigation was initiated in 2010 when results from the ROADMAP trial showed that patients with type 2 diabetes taking olmesartan had an increased risk for cardiovascular death.

Now the FDA says that it "has found no clear evidence of increased cardiovascular risks associated with" olmesartan in diabetic patients. The agency says it will not change the recommendations for olmesartan's use but will include new data about the drug in its label.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement